Selling rights of Zoladex medication sold to TerSera for USA and Canada

Posted by Asuka on July 4th, 2019

AstraZeneca’s new plan of Action

AstraZeneca has sold their right to sell Zoladex (generic of Goserelin) in the United States and Canada to TerSera Therapeutics LLC, headquartered at Illinois, USA. And the main reason for this big move is because AstraZeneca is keen to focus more on newer Oncology products.

The deal is expected to be finalized by the end of March 2017, and it will see AstraZeneca receive an upfront payment of 0 million for foregoing of their rights to sell Zoladex in the United States and in Canada. The deal also provides with AstraZeneca with double-digit ongoing payments based on Quarterly Sales and there also includes a clause of AstraZeneca receiving additional million, if Zoladex (Generic of Goserelin) meets the series of desired sales milestones.

This agreement will allow AstraZeneca retain a significant share of Zoladex’s value in Canada as well as in the United States, allowing us to give more attention to develop new Oncology medicines said the Executive Vice President of global product and portfolio strategy Mark Mallon.

And with TerSera Therapeutics dedicated focus to expand the potential of this medicine, the patients will have a continued and ease access to this medicine.

Even though AstraZeneca had sold the selling rights for Zoladex, they will continue to manufacture Zoladex at their production facility in Cheshire to make sure there is a continued supply of Zoladex across Canada and the United States; for the time being.

Zoladex (generic of Goserelin) used for the treatment of Cancer majorly Breast and Prostate Cancer along with gynaecological disorders, is a luteinizing hormone-releasing hormone agonist injection.

Zoladex has seen its sales volume decreasing in the recent years, With a Global sale of 6 million in 2015 to 6million in 2016 a fall of 4% and Zoladex (generic of Goserelin) once was biggest selling Oncology medicine in AstraZeneca’s Arsenal.

The Chief Executive of AstraZeneca Pascal Soriot has stated that 2017 would be “defining year” in the company’s pipeline as with Zoladex’s selling rights been sold, they are more determined towards newer and more innovative Oncology medicines.

And among the newer Oncology medicines are Osimertinib (used in the treatment of Non-small Cell Lung Cancer) delivering a staggering 3million in the first year of its launch in the market and Durvalumb which is due for regulatory verdicts later this year.

Market Researchers and Analysts have forecasted Tagrisso (Osimertinib) to bring about billion in global sales with the help of an anticipated first-line indication ruling and new Non-small Cell Lung Cancer approvals, and they have already marked Durvalumb a potential Blockbuster Oncology medicine with global sales of billion by 2020.

Goserelin / Zoladex price information

The information provided on the page is meant for the purpose of being helpful and educational. It should not be considered as medical advice.